This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-54452840

Johnson & Johnson

Drug Names(s): COR-1

Description: COR-1 is a cyclic peptide which inhibits the effects of the stimulatory beta-1 autoantibodies by scavenging and neutralising them.

Deal Structure: COR-1 was originally developed by CorImmune.

Johnson & Johnson (Janssen) and CorImmune
In June 2012, Janssen announced it completed the acquisition of CorImmun for an undisclosed upfront payment and a contingent future clinical milestone payment. Under terms of the agreement, Janssen and its affiliates immediately assume full development and global commercialization responsibilities for COR-1.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug